• InnerScope Hearing Technologies prepares to launch first in a series of National Hearing Loss Blitz Media Campaigns to raise hearing problems awareness and showcase company’s unique hearing aid solutions as US government pushes for more accessible hearing aids market
• Campaign expected to drive sales of its revolutionary Direct-to-Consumer, rechargeable app-controlled hearing aids and other services such as subscription plans which allow patients access to a complete set of affordable hearing aids for less than $45 per month
• InnerScope Hearing Technologies remains committed to improving quality of life for 70 million people in North America who suffer from hearing impairment and potentially 1.5 billion worldwide

InnerScope Hearing Technologies (OTC: INND) appears poised to disrupt the traditional hearing technology space by making affordable hearing aid technology accessible for affected patients across America and potentially beyond. The company has announced the launch of its efforts to contribute to the National Hearing Loss Blitz Media Campaign in a commitment to reach 48 million Americans suffering from hearing issues who can benefit from its unique Direct-to-Consumer technology (https://ibn.fm/u4BbJ). As an emerging disruptive leader in the hearing industry, InnerScope is planning more national multimedia marketing campaigns over the next months to generate public awareness about the hearing loss problem and help consumers control their growing hearing issues. The company teamed up with New to The Street TV, the partner trusted with the production, broadcasting, and distribution of marketing collateral about hearing loss awareness and InnerScope’s Direct-to-Consumer Bluetooth app-controlled, self-adjusting rechargeable hearing aids that give patients access to hearing treatments without the need of medical professionals. Hearing loss is a growing problem affecting a significant number of Americans. According to the Centers for Disease Control and Prevention, around 16% of the adults in the US have hearing issues, twice as many as some other prevailing diseases such as diabetes or cancer (https://ibn.fm/GbyZO). But since hearing aids are so expensive — on average, they cost more than $5,000 per pair — only 14% of patients can afford them. This problem recently prompted an executive order from President Biden to make hearing aids more affordable and available over the counter without any prior medical evaluation (https://ibn.fm/V6eOW). Today, many patients are unaware that direct-to-consumer hearing aids are available online without any medical evaluation — and InnerScope is poised to get this message out as a company offering affordable and timely hearing aid solutions to patients across the US. Through the campaign, the company aims to put a spotlight on the importance of early treatment while showcasing its game-changing Direct-to-Consumer hearing aids and its new Hearing Health Flexible Subscription Plans. These easy-to-enroll plans allow patients to order a complete set of InnerScope’s Direct-to-Consumer rechargeable app-controlled hearing aids with no prior medical examination or professional help. The campaign, intended to include 156 digital billboards throughout lower Manhattan, New York City, New York, and TV commercials to be broadcast on prominent media outlets such as Bloomberg, CNN, CNBC, Fox Business Network, Fox News, MSNBC, and Newsmax TV, is expected to drive sales of InnerScope’s hearing aids, available online through its digital store. Poised to shift hearing health care from expensive traditional brick-and-mortar hearing care clinics to consumers’ homes, InnerScope targets a sizable market that includes around 70 million patients with hearing-related problems across North America. In addition, the global addressable market counts 1.5 billion people suffering from hearing impairment or hearing-related issues around the world. For more information, visit the company’s website at www.INND.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• AnPac Bio-Medical Science Co. Ltd. is a biotechnology company focused on early cancer screening and detection
• The company aims to develop, distribute and deploy its Cancer Differentiation Analysis (“CDA”) technology to change the way people approach cancer screening
• CDA is powered by a database of over 200,000 samples and cases, providing a new way to approach disease and cancer screening
• The company’s management team comprises professionals in both the United States and China who are knowledgeable and well educated in cancer screening and detection
• The global cancer diagnostics market is expected to reach $249.6 billion by 2026

AnPac Bio-Medical Science Co. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection. The company develops, distributes and deploys accessible early disease detection devices with an aim of changing the way people approach cancer screening. AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance. AnPac Bio-Medical has clinical laboratories in the United States and China, with 142 issued patents as of March 31, 2021. Its corporate headquarters is located in Shanghai, China, while its U.S. headquarters is situated in Philadelphia, Pennsylvania. The company operates two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States. Cancer Differentiation Analysis (“CDA”) Cancer Differentiation Analysis (“CDA”) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form. Most liquid-based cancer screening and detection technologies focus on biochemical signals, like conventional biomarkers and genomic signals, such as ct-DNAs and CTCs (circulating tumor cells in the blood). These typically only determine whether or not cancer has occurred at a fixed point in time. CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future – all through a standard blood test, at a competitive price point. AnPac Bio-Medical’s CDA is powered by a database of over 200,000 samples and cases and serves as a new way to approach disease and cancer screening. The device uses an integrated system of sensors to detect several biophysical signals at the cellular, protein and molecular levels. CDA leverages a proprietary algorithm to synthesize the data, effectively generating a personalized risk assessment for evaluated patients. Through CDA technology, AnPac Bio-Medical aims to address a number of goals, including:

• Innovate – AnPac Bio-Medical is an innovator in the cancer screening industry, with CDA research ongoing since 2008, and commercial operations beginning in 2015. AnPac considers itself a thought leader in developing multi-cancer screening.
• Detect – AnPac Bio-Medical detects early signals of threatening cancer and its location within the body.
• Identify – CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity rates.
• Provide – The company’s platform provides multi-level, multi-parameter analysis using proprietary diagnostic algorithms, which results in accurate and easy-to-understand results.
• Proven – A fully operational analysis of over 200,000 test samples has been run to date. CDA technology has been shown to identify pre- and early-stage cancers in patients previously diagnosed as “cancer-free” through traditional methods.
• Biophysical Properties – CDA analyzes biophysical properties in human blood and the correlation between biophysical properties and cancer occurrence.

Market Outlook AnPac Bio-Medical is exploring detection of other types of cancers leveraging its innovative CDA technology and multi-cancer screening and detection tests, which could open significant opportunities on the global cancer diagnostics market. According to a report by Grand View Research, the cancer diagnostics market is expected to reach $249.6 billion worldwide by 2026 (https://ibn.fm/EMdoS). The market is expected to grow at a CAGR of 7% during the forecast period. Management Team Dr. Chris Yu is the Co-Founder and Chief Executive Officer of AnPac Bio-Medical. He has enjoyed a successful career as an innovator in life sciences, technology and engineering. Dr. Yu has worked for three U.S. Fortune 500 companies and is the first/principal inventor of over 300 patent applications spanning semiconductors, materials and life science. He has a proven history of developing cutting-edge products with long-term profit and sustainability. Dr. Yu was born to a medical doctor’s family and went to medical school. He later switched his major to physics and received his bachelor’s and master’s degrees in physics from the University of Missouri-Kansas City Campus and a doctoral degree in physics from Pennsylvania State University. Both of his dissertations addressed innovative detection techniques. Dr. Herbert Yu is the Co-Founder and Chief Medical Officer of AnPac Bio-Medical. He is a renowned expert in molecular epidemiology, with training in medicine and chemical biochemistry. Dr. Yu has a 20-year career in leading-edge cancer research, including breakthrough work in areas of carcinogenic factors. He is a professor and research director at the University of Hawaii and an adjunct professor at Yale University. He received his bachelor’s degree in medicine from Shanghai First Medical College. Dr. Yu also received a science degree in epidemiology and a Ph.D. in clinical biochemistry from the University of Toronto. Jingiu (Edward) Tang is the company’s Chief Financial Officer. He previously served as a global internal auditor at Natuzzi S.p.A. Mr. Tang also worked at Beijing Dongshen CPA and Shanghai De’an CPA, providing external audits, finance and tax advisory services across different industries and sectors. He is a Certified Public Accountant in Australia. Mr. Tang received his bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University, and his bachelor’s degree in law from Southwest University of Science and Technology in China. Weidong Dai is the company’s China General Manager. He previously served as a general partner at Stirrfir Investment Management Co. Mr. Dai has also served as the chairman of RTS Management (Shanghai) Co., and as managing director of Hong Kong Pro-Health Technology Co. and Shanghai Pro-Health Medical Devices Co. He has published a number of medical research papers and research articles in professional journals. Mr. Dai was awarded the Hong Kong Industrial Award for a medical device that he led in research and development. He earned his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from the Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics. For more information, visit the company’s website at www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

• Emaginos is first company with actionable plan to transform, improve public schools rather than replace them
• The company has support from both major U.S. teachers’ unions
• Emaginos filed a provisional patent application for its proprietary EdManage platform

In a space where investment windows are few and far between, Emaginos offers a unique opportunity for altruistic individuals to change the educational landscape (please see website if interested in investing). The company, which is raising capital from the general investing public under provisions of Regulation A, is seeking $3 million to implement its proven, patent-pending K-12 education system and transform the nation’s educational system. “Emaginos is the first company with an actionable plan to transform and improve public schools rather than replace them,” the company explains (https://ibn.fm/VkLX5). “The Emaginos model utilizes existing funding, facilities and staff to improve educational approaches and outcomes, in many cases saving school districts money as they subscribe to and implement the Emaginos platform.” And while the Emaginos system is designed to ultimately help schools and districts save money, the company is also working to ensure its investors may realize return on their investments. As schools adopt the system, the cost to implement the program decreases while an increasing number of schools climb aboard. “Our solution is a subscription service,” explains Emaginos president Allan Jones (https://ibn.fm/qcfgH). “We have no local district executives collecting outrageous salaries. The teachers run the schools using the tools and resources provided by Emaginos. For a reasonable fee, Emaginos provides a comprehensive suite of services that empowers and enables the school district to transform itself into an engaging learning environment. The districts still control their schools. For the same money they were spending on a defective program, we enable them to deliver a high-quality education.” The Emaginos system is gaining support — and momentum. The company reports that it has support from both major U.S. teachers’ unions, the American Federation of Teachers and the National Education Association. That backing strengthens the company’s position as it moves forward toward widespread marketing and implementation of the Emaginos model in public schools throughout the United States. In addition, the company recently has filed a provisional patent application with the United States Patent and Trademark Office for its proprietary EdManage platform, an educational technology (edtech) analytics platform that aggregates and analyzes all of a school district’s data to deliver actionable information to users throughout the system (https://ibn.fm/TpQG9). EdManage integrates all of the devices and applications within a school system that traditionally operate independently. Emaginos is a company dedicated to transforming K-12 public schools into a model composed of integrated, proven best practices. The company opposes replacing public schools with charter schools or damaging public schools by draining resources through vouchers or school choice programs. Emaginos firmly believes in restoring the concept of the neighborhood schools as the center of the community. To achieve this vision, Emaginos begins by transforming an initial school in the district into a charter school as a model for the transformation. The charter model, in this instance, uses the concept as it was intended, to test and demonstrate the effectiveness and efficacy of a new model in the district. After the model is successful in the charter school, the lessons learned are used to directly transform the rest of the schools into effective public schools. For more information about Emaginos and to learn about investment and shareholder opportunities, visit www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos

• Bloomberg article reports that sales of classic cars have remained “positively stable” during global pandemic
• Two key acquisitions help firmly establish PRPI’s position in multibillion-dollar classic car market
• CEO notes that PRPI’s acquisition of Worldwide Auctioneers will lead to company’s greater growth

While COVID-19 may have dampened the new-car market, a recent Bloomberg article noted that the global pandemic had little impact on the sales of classic cars (https://ibn.fm/lkWMO). That’s good news for Perpetual Industries (OTC: PRPI), which earlier this year announced two key acquisitions — the Worldwide Group LLC, operating as Worldwide Auctioneers, and AutoGrafic Software System — both aimed at firmly establishing the company’s position in a multibillion-dollar classic car market. “From Bentley to BMW, Polestar to Porsche, new-car sales have slumped in 2020,” Bloomberg reported. “Sales of classic cars, on the other hand, have remained positively stable.” The article quoted Brian Rabold, vice president of valuation services at Hagerty, a company that insures classic and collectible cars, who noted that last year “was a very strange year. There was a lot of appetite to buy cars.” Rabold observed that the proliferation of online platforms from auction houses and startups alike fueled consumer hunger. “A lot of people had more time, they weren’t traveling, they weren’t leaving the house. You could just sit in front of the computer and shop. All of that conspired to make 2020 really strong. . . . In unstable times, car people tend to hang onto their blue-chip cars and get other ones, so there’s a lot of interest that has picked up there.” PRPI reports that the U.S. classic car market has seen steady expansion over recent years, with revenue reaching approximately $12.63 billion in 2020 and forecasted to total an estimated $15.52 billion by 2023, representing a CAGR of more than 7% (https://ibn.fm/Fydhj). Classic car dealers have cornered a significant portion of this market opportunity. With that market potential as a backdrop, Perpetual Industries completed its acquisition of Worldwide Auctioneers in January 2021 (https://ibn.fm/9wa4U). A U.S.-based boutique auction company specializing in the sale and acquisition of classic vintage motorcars at auction around the globe, Worldwide Auctioneers also has a stellar reputation for offering an extensive range of personalized services to collectors, including private sales, appraisal, collection direction and consultancy, estate planning, and asset management. “I am excited to welcome the entire Worldwide team to Perpetual’s umbrella,” said PRPI CEO Brent Bedford. “Their entrepreneurial spirit is a good match with ours, and I am looking forward to achieving greater growth in Perpetual while playing a key role in reaching the future goals of Worldwide.” A few months later, in April, PRPI took another critical step forward with the acquisition of AutoGrafic Software System, a software as a service (SaaS) and social application that utilizes cutting-edge technology to host many aspects of automotive promotion and preservation. AutoGrafic targets global collector car and automotive enthusiasts who want a unique, multifaceted, interactive automotive experience that is focused on a visual-based social community, collection management, social events, auctions, insurance, research, preservation and historical documentation. “This acquisition provides another foundational piece in our quickly expanding blockchain division and, in addition to outstanding software, augments our team with some truly exceptional talent,” said Bedford. “It will also greatly benefit Worldwide Auctioneers, our newly acquired wholly owned subsidiary, by bringing much-needed new technology and innovation to their customers and the collector car industry at large.” Perpetual Industries is an incubator for the development of new and innovative energy-efficient technologies. The company’s mission is to “perpetuate industry” by bringing value-added technologies to market. The company is expanding its expertise and knowledge of energy-efficient technology by developing low-cost, green-energy-powered solutions for a variety of industries while continuing its research, development and commercialization of the XYO Technology in key applications. For more information, visit the company’s website at www.PerpetualIndustries.com. NOTE TO INVESTORS: The latest news and updates relating to PRPI are available in the company’s newsroom at https://ibn.fm/PRPI

• Lexaria just completed dosing for its second human clinical study, HYPER-H21-2
• The study sought to understand the human response to Lexaria’s DehydraTECH 2.0-enabled CBD
• The company also announced that its DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the United States
• Lexaria also expanded its intellectual property portfolio with the allowance of its second patent in Japan
• It also received US$3,817,643 from warrant exercises, proceeds from which will be used to advance the company’s research and development program and for its general corporate purposes

Lexaria Bioscience (NASDAQ: LEXX) has been making incredible strides in 2021 as it works towards achieving its business plan objectives. At the beginning of the year, the company set out to conduct three human clinical studies, two of which are underway at the time of this article.  Its most recent human clinical study, HYPER-H21-2, dosing was completed in July 2021 and was designed to understand better the human response to Lexaria’s DehydraTECH 2.0-enabled CBD (https://ibn.fm/4eBs1). The company projects that preliminary results would be available for reporting either in September or earlier. This second human clinical trial involved 16 human volunteers who previously dealt with hypertension or were mildly hypertensive at the time of the study. Each of the 16 participants received three different doses of 150 mg each of DehydraTECH(TM) 2.0-enabled CBD versus a placebo for a total dose of 450 mg. the study involved a 24-hr continuous ambulatory (portable) monitoring of vitals such as blood pressure and heart rate, while also taking into consideration evaluations of central arterial stiffness, physical activity as well as sleep quality. Lexaria hopes to commence with the third and last human clinical hypertension study of 2021, HYPER-H21-3. It will offer updates in due course. As the company celebrates the progress achieved through this second human clinical trial, Lexaria marked another massive milestone by increasing its market reach in the United States (“US’).  With partnerships with Cannadips, New World CBD, Impact Naturals and Amari, among others, Lexaria’s DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the US (https://ibn.fm/fOYnK). In an official statement from Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria, he noted that “Lexaria technology is enabling increased market share and sales growth for our continually growing list of corporate clients. We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.” Lexaria is a global leader in enhancing the overall speed and efficiency of orally-delivered fat-soluble active molecules and drugs. With its drug delivery technology and its advancing intellectual property (“IP”), the company is transforming existing consumer products and medications that may improve their availability and bioavailability. Its flagship technology, DehydraTECH(TM), improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream, primarily by promoting healthier oral ingestion methods and increasing the effectiveness of the fat-soluble active molecules. As of early July 2021, Lexaria had 20 patents falling under 13 different patent families. In July, it got its second patent in Japan titled “Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof.” This became the company’s 21st patent granted to the company and the 17th patent granted to its first patent family. Also, in July, Lexaria received US$3,817,643 from warrant exercises. The company issued the warrants in relation to its January 2021 public underwritten offering. Under this offering, the shares and warrants issued were registered according to a Form S-1 Registration Statement. They were excised into 580,189 shares of voting common stock of the company at an exercise price of US$6.58 per share (https://ibn.fm/IeVUp). Lexaria noted that all proceeds received from the warrant exercises would be used to continue advancing the company’s investigational research program and for general corporate purposes. With these critical milestones achieved so far, Lexaria is confident that its business plan objectives, along with all its operations, are now all set and fully funded, well into the 2022. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Avricore Health signed the first amendment to its supplier distribution agreement between subsidiary HealthTab and Abbott
• The amendment adds to the agreement Abbott’s ID Now(TM) molecular testing device, which will bring in onsite testing and reporting capabilities for SARS-CoV-2 (Covid-19), RSV, Influenza A & B, and Strep
• Avricore also announced its partnership with Ellerca Health, which will see the companies use their respective technologies (Avricore’s HealthTab and Ellerca’s 360Care app) to support patient needs at community pharmacy level

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) recently made several key strides in its quest to become the world’s leader point-of-care technologies within community pharmacy. On July 26, the company announced the signing of the first amendment to its supplier distribution agreement between its wholly owned subsidiary and flagship offering, HealthTab(TM) Inc, and Abbott (NYSE: ABT), the global healthcare company and diagnostics leader, in Canada (https://ibn.fm/5IKuw). Under the original supplier distribution agreement, first signed on May 31 this year (https://ibn.fm/oWz8Y), HealthTab received the mandate to distribute in Canada Abbott’s Afinion(TM) 2 – a small, fast, and multi-assay analyzer providing valuable point-of-care testing to patients – and associated tests for diabetes and heart-disease screening in community pharmacies, including HbA1c testing – also known as A1C. A few days later, Avricore signed the Master Agreement with Canada’s largest pharmacy network, Shoppers Drug Mart, that would enable patients to access its HealthTab platform – an innovative point-of-care blood screening and health-data management platform – integrated with Abbott’s Afinion 2 analyzers. The company has since completed a test rollout of its platform in which over 600 results were reported in the week-and-a-half trial period (https://ibn.fm/DDwar). Following the test rollout, a pharmacist and associate owner of a Shoppers Drug Mart located in Mississauga, Ontario, expressed his excitement at having HealthTab in his store because the platform would demonstrate a new, better way of doing pharmacy practice. “This is really profound because having access to lab-accurate results at our fingertips means we can better help family physicians by conducting regular follow up using advanced diagnostics with our diabetic and cardiovascular patients more effectively,” Mohamed Adel Elsabakhawi had said (https://ibn.fm/lcdQ9). In what will surely expand the capabilities of pharmacists like Mohamed in addition to helping detect infections before they spread, the first amendment adds to the distribution agreement Abbott’s ID Now(TM) molecular testing device, which will introduce onsite testing and reporting capabilities for SARS-CoV-2, RSV, Influenza A & B, and Strep. “A missing link today in the response to COVID-19 and general virus outbreak is the ability to get confirmatory testing and reliable, real-time reporting in a low-barrier setting,” said Avricore CEO Hector Bremner. “With ID Now on the HealthTab network in community pharmacy, patients can know what they have and get focused treatment and prevent spread through better information.” Avricore, which expects to add more analyzers and testing capabilities, also signed a partnership agreement with Ellerca Health Corp, a Toronto, Canada-based digital health organization revolutionizing the personal experience and health outcomes of people living with chronic diseases (https://ibn.fm/1EteR). The mutual collaboration on a project-by-project basis will see the companies use Avricore’s HealthTab and Ellerca’s 360Care(TM) to support patients’ needs at the community pharmacy level. The technologies will prioritize early detection, screening, and the consistent management of chronic diseases, like diabetes, as well as support better health outcomes for people living with these conditions. The partnership will, for instance, allow Ellerca’s members to easily access A1C testing at local pharmacies and improve the speed of results. The 360Care is a supportive, app-based digital platform that facilitates self-management of chronic diseases and allows patients to be in control of their own treatment. By working together with patients in this way, the platform lowers the time and cost of reactionary treatments and shifts the focus to preventative care by reducing and eliminating symptoms of chronic conditions. Avricore and Ellerca are looking forward to bringing to community pharmacy enhanced patient services that combine HealthTab’s diagnostics and data-management systems with the ongoing coaching and support of 360Care. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Emaginos is committed to solving two major education problems
• Investing in Emaginos provides an opportunity to do good and do well, says company president
• Company plans to transform America’s public schools to a more effective model based on a carefully integrated set of proven best practices

Emaginos, a company raising new capital under provisions of Regulation A of the Securities Act of 1933 (please see website if interested in investing), is seeking $3 million to begin the transformation of the K-12 education system in the United States. Based on the company’s proprietary Discover Learning System (“DLS”), Emaginos offers investors an opportunity to attempt to realize return on their investment while fixing one of the nation’s fundamental problems — its educational system. Emaginos is committed to solving two major problems, according to a recent President’s blog (https://ibn.fm/xhXyg). “The first is fixing . . . the outdated and test-bound K-12 public school system,” writes Emaginos president Allan Jones. “The second is enabling teachers and parents to benefit financially from the transformation – doing good while doing well.” Jones explains what doing good while doing well means: “Doing good refers to behaving altruistically or charitably. Doing well refers to being financially secure,” he writes. “Looking at Maslow’s Hierarchy (https://ibn.fm/UZisi) tells us that instinctually we have to focus on doing well before we can consider doing good. Investing in Emaginos provides an opportunity to do both simultaneously.” In his blog, Jones notes that “you don’t need to be a researcher to be aware that America’s public schools are failing to meet the 21st-century educational needs of our children and, therefore, of our country’s future. The current lack of digital and educational equity inherent in America’s K-12 public education system is a shameful disgrace. The ‘teach-to-the-test’ and related reliance on high-stakes testing is turning off our children and driving dedicated teachers from their chosen profession. At the same time, profiteers and elected officials have realized they can use (or abuse) our schools for their financial or political gain. “Along comes Emaginos,” Jones continues. “Our plan is to transform America’s public schools to a more effective model based on a carefully integrated set of proven best practices. Note that we are not seeking to create more charter schools. We are not seeking to take over and operate schools. We are not seeking to eliminate teachers’ unions.” So what is Emaginos’s strategy? Emaginos uses existing facilities, staff, students and faculty, explains Jones. “We provide them a comprehensive transformational suite of services and resources that enable the local schools to become engaging learning environments producing entrepreneurial lifelong self-directed learners. Teachers run the schools.” As far as cost, Emaginos products and services require an initial cost to develop, but once developed, they can be sold many times at very low incremental cost. “The first schools will break even,” Jones explains. “Subsequent schools or districts will provide the same revenue but cost progressively less to transform and support. Any profits will enable Emaginos investors to potentially realize a return on their investments as we continue to improve our products and services and grow the business.” The opportunity to both earn a profit and fix a fundamental problem in the country today is an unusual proposition in the world of investing. Jones’s invitation is simple: “If you are interested in joining us in doing good for our students while possibly realizing a return on investment, go to https://Emaginos.com/reasons-to-invest to learn more.” For more information about Emaginos and to learn about investment and shareholder opportunities, visit www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos

• The company has filed patent applications for two routes of chemical synthesis of ibogaine – offering potential advantages of improved isomeric purity, chiral purity, and easily isolated intermediate compounds
• Preliminary data indicates that the drug shows promise as a treatment for neuropathic pain and migraines, as well as the treatment of addiction
• The company is positioned to engage several markets, including digital therapeutics and research

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”), a diversified life sciences company at the forefront of the mental health industry, recently announced the launch of its second manufacturing stage of pharmaceutical-grade ibogaine to be used in psychedelic clinical research. During this stage of manufacturing, the company will be assessing the quality of the synthetic ibogaine to be produced at scale to determine the timing and cost for commercial-scale manufacturing (https://ibn.fm/xOXo9). Kelsey Ramsden, President and CEO of MINDCURE, spoke on the manufacturing goals stating, “We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes. We are currently working on proving the ability to scale up the production, and our next step will be to test the ibogaine to ensure it meets the highest standards of the pharmaceutical-grade product.” Ibogaine is a psychoactive substance that can be found naturally in the roots of the African iboga tree. The company is actively researching ibogaine as a potential treatment for traumatic brain injury and other related conditions. All preliminary data show that the drug may also yield promising results as a treatment for neuropathic pain and migraines. In addition, research also indicates that ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addiction. MINDCURE has filed U.S. provisional patent applications for two routes of chemical synthesis of ibogaine. Both routes may provide advantages of improved isomeric purity, increased chiral purity, and more easily isolated intermediate compounds. Both are currently under assessment to determine the preferred method for further developing the compound (https://ibn.fm/ojpg5). Chief Medical Officer Joel Raskin discussed the natural iboga plant as a precious resource, stating, “Manufacturing synthetic ibogaine and patenting our process would create the opportunity for synthetic ibogaine to be used by researchers conducting clinical trials and, eventually, by clinicians providing psychedelic therapy. Our company’s research team would also have access to this sustainable drug supply.” MINDCURE is positioned to disrupt several different market spaces through its technology, research, and products, including the digital therapeutics space, which covers health interventions delivered through a smart device to induce a behavioral change in the patient. The company’s leading foray into the digital therapeutics space is iSTRYM, an AI-driven software platform that enables personalized and calculated outcomes in psychedelic therapy. The global digital therapeutics market was valued at $2.88 billion in 2019, but it is expected to reach $13.8 billion by 2027 with a CAGR of 20.5% during the forecast period (https://ibn.fm/793EJ). The global market for drug addiction therapy, where ibogaine can be a potential game changer, was valued at $17.65 billion in 2019 and is expected to grow at a CAGR of 7% during the forecast period, resulting in a value of $31.17 billion by 2027 (https://ibn.fm/oAI5T). For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• Brain-Computer Interface (“BCI”) market is expanding rapidly, expected to double to USD 406 billion by 2026
• BCI technology, designed to acquire brain signals, analyze and translate them into commands, is one of key driving forces behind EEG technology growth
• Brain Scientific appears poised to capitalize on this novel technology as its applications expand from medical settings to training, consumer engagement, entertainment, and more

The Brain-Computer Interface (“BCI”) field is growing rapidly, representing one of the main driving factors behind the expansion of EEG technology. As the provider of EEG technology, Brain Scientific (OTCQB: BRSF) appears well placed to leverage this rapid growth of the industry expected to double in size by 2026 (https://ibn.fm/F5LOs). BCI technology refers to solutions that record the brain signal from the surface of the cortex, using sensors placed over the scalp or signaling devices implanted in the brain. As a promising approach to overcome paralysis by decoding brain signals directly from the scalp and translating them into movements of a virtual or robotic effector, BCI can provide opportunities for motor rehabilitation from a number of conditions, including spinal cord injury, traumatic brain injury, and stroke (https://ibn.fm/C9Dom). This powerful technology can even help patients who lost the ability to speak to communicate. A recent study reports the first patient ever to produce whole words via a computer that decodes his brain’s messages through electrodes implanted in his brain (https://ibn.fm/gr3j7). Enabling advances never possible before, the BCI space is expanding rapidly, and EEG is an essential part of that landscape. Recent market research reveals that the BCI market is expected to grow at a 12.4% CAGR over the next five years, reaching $409.3 million by 2026 — more than double compared to $203 million reported in 2020. Main growth drivers include swelling demand from healthcare, entertainment, gaming, communication, and control. Traditionally, EEG-based BCI technology has been geared towards medical applications where it was utilized to help disabled patients to interact with the external world. However, with a shift of focus towards people with normal health, the technology is no longer constrained to medical settings only. For example, training — including athletic, military, and occupational — and fields such as consumer engagement and entertainment are becoming target groups that would likely benefit from using EEG-based BCI systems (https://ibn.fm/oV87E). As the application space for EEG-based BCI solutions expands, Brain Scientific appears poised for rapid growth. With its current and future products, including disposable EEG headsets for neurological patients, long-term monitoring solutions, and AI-empowered technology for recording brain activity, the Company appears well-placed within the growing brain monitoring space. Committed to pushing the boundaries of what’s possible in the neurology space, Brain Scientific brings the ground-breaking technology that aim to enable what was inconceivable until recently. For more information on Brain Scientific Inc., visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• FingerMotion’s SMS & MMS, TPS, and Big Data divisions generated $6.00 million in revenue for Q1 2022
• The SMS & MMS and TPS businesses’ Q1 2022 revenues increased significantly compared to Q1 2021 figures
• Q1 2022 also marked the second consecutive quarter in which the big data division generated revenue, and a Q/Q increase at that
• FingerMotion is also targeting the accretive rich communications services (“RCS”) segment, with RCS expected to form its fourth division

On July 15, evolving technology company FingerMotion (OTCQX: FNGR) released its Q1 2022 results in which it reported record quarterly revenue of $6.00 million, generated by its SMS & MMS, Telecommunications Products & Services (“TPS”), and Big Data divisions. The SMS & MMS division’s revenue was up 77% or $1.81 million compared to Q1 2021, while the TPS division’s revenue grew by 341% or $1.34 compared to a similar period a year before (https://ibn.fm/S1osq). Q1 2022 also marked the second consecutive quarter of revenue from the Big Data division with reported revenue of $98,715. This figure represented a 198% quarter-over-quarter increase, given that in Q4 2021, the division generated $33,077. “Growth continues to be fueled by an expansion of subscribers in new regions along with larger purchases of SMS from our corporate clientele,” commented FingerMotion CEO Martin Shen. “This is the second consecutive quarter of Big Data revenues, and we expect it to continue and eventually outpace our existing revenue streams.” The Q1 2022 results’ announcement followed on the heels of the June 2 release of the company’s financial results for the fiscal year ended February 28, 2021. Here, FNGR reported that its SMS & MMS business and TPS division posted annual revenue growths of $6.13 million (84%) and $1.39 million (76%), respectively, compared to the previous financial year. The two businesses cumulatively contributed to a record annual revenue of $16.68 million (https://ibn.fm/ml4Fh). FingerMotion anticipates that if the current trajectory defined by the Q1 2022 results continues, its revenue for FY 2022 may exceed $24 million, which would represent a year-over-year jump of over 44%. The projected increase is likely to result from its existing operations, suggesting that the SMS & MMS, TPS, and Big Data businesses will continue soaring throughout the remainder of FY 2022. Meanwhile, FNGR is also targeting another high growth opportunity in rich communication services (“RCS”), expected to form the company’s fourth division. Rich communication services are emerging as a formidable technology enabling users to access various advanced capabilities from their native messaging service without installing a third-party application. Such capabilities include group chat, video calling, file sharing, and even additional features such as the ability to book a restaurant or flight. RCS has revolutionized text-based messaging by eliminating previous constraints that limited it to merely sending short text messages. With RCS, messaging has become a platform (https://ibn.fm/pfZPX). MarketsandMarkets projects that the global RCS market will grow from $5.2 billion in 2020 to $11.7 billion by 2025, representing a CAGR of 17.6% CAGR. The Asia Pacific (“APAC”) region is expected to record the highest growth rate during the forecast period, with China playing a dominant role as a key contributor to the growth. The study credits the region’s increasing populations, advanced SMS systems, expanding retail industry, rise in smartphone usage, and growing mobile payments for being behind the growth (https://ibn.fm/PVlm3). FingerMotion identified the accretive opportunities within the emerging RCS segment and, in March 2020, allocated resources for the R&D of a proprietary RCS platform. “This RCS platform is expected to be a proprietary business messaging platform that enables businesses and brands to communicate and service their customers on 5G infrastructure, delivering better user experience, more efficiently and cost-effectively. This is expected to open up a new marketing channel for the company’s current and prospective business partners,” reads a segment from FingerMotion’s annual report filed with the SEC as form 10-K (https://ibn.fm/Elhme). For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR